Laurie E Davies1, Andrew Kingston1, Adam Todd2, Barbara Hanratty1. 1. Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom. 2. School of Pharmacy, Newcastle University, Newcastle upon Tyne, United Kingdom.
Abstract
BACKGROUND: Polypharmacy is potentially harmful and under-researched amongst the fastest growing subpopulation, the very old (aged ≥85). We aimed to characterise polypharmacy using data from the Newcastle 85+ Study-a prospective cohort of people born in 1921 who turned 85 in 2006 (n = 845). METHODS: The prevalence of polypharmacy at baseline (mean age 85.5) was examined using cut-points of 0, 1, 2-4, 5-9 and ≥10 medicines-so-called 'no polypharmacy', 'monotherapy', 'minor polypharmacy', 'polypharmacy' and 'hyperpolypharmacy.' Cross-tabulations and upset plots identified the most frequently prescribed medicines and medication combinations within these categories. Mixed-effects models assessed whether gender and socioeconomic position were associated with prescribing changes over time (mean age 85.5-90.5). Participant characteristics were examined through descriptive statistics. RESULTS: Complex multimorbidity (44.4%, 344/775) was widespread but hyperpolypharmacy was not (16.0%, 135/845). The median medication count was six (interquartile range 4-8). Preventative medicines were common to all polypharmacy categories, and prescribing regimens were diverse. Nitrates and oral anticoagulants were more frequently prescribed for men, whereas bisphosphonates, non-opioid analgesics and antidepressants were more common in women. Cardiovascular medicines, including loop diuretics, tended to be more frequently prescribed for socioeconomically disadvantaged people (<25th centile Index of Multiple Deprivation (IMD)), despite no difference in the prevalence of cardiovascular disease (p = 0.56) and diabetes (p = 0.92) by IMD. CONCLUSION: Considering their complex medical conditions, prescribing is relatively conservative amongst 85-year-olds living in North East England. Prescribing shows significant gender and selected socioeconomic differences. More support for managing preventative medicines, of uncertain benefit, might be helpful in this population.
BACKGROUND: Polypharmacy is potentially harmful and under-researched amongst the fastest growing subpopulation, the very old (aged ≥85). We aimed to characterise polypharmacy using data from the Newcastle 85+ Study-a prospective cohort of people born in 1921 who turned 85 in 2006 (n = 845). METHODS: The prevalence of polypharmacy at baseline (mean age 85.5) was examined using cut-points of 0, 1, 2-4, 5-9 and ≥10 medicines-so-called 'no polypharmacy', 'monotherapy', 'minor polypharmacy', 'polypharmacy' and 'hyperpolypharmacy.' Cross-tabulations and upset plots identified the most frequently prescribed medicines and medication combinations within these categories. Mixed-effects models assessed whether gender and socioeconomic position were associated with prescribing changes over time (mean age 85.5-90.5). Participant characteristics were examined through descriptive statistics. RESULTS: Complex multimorbidity (44.4%, 344/775) was widespread but hyperpolypharmacy was not (16.0%, 135/845). The median medication count was six (interquartile range 4-8). Preventative medicines were common to all polypharmacy categories, and prescribing regimens were diverse. Nitrates and oral anticoagulants were more frequently prescribed for men, whereas bisphosphonates, non-opioid analgesics and antidepressants were more common in women. Cardiovascular medicines, including loop diuretics, tended to be more frequently prescribed for socioeconomically disadvantaged people (<25th centile Index of Multiple Deprivation (IMD)), despite no difference in the prevalence of cardiovascular disease (p = 0.56) and diabetes (p = 0.92) by IMD. CONCLUSION: Considering their complex medical conditions, prescribing is relatively conservative amongst 85-year-olds living in North East England. Prescribing shows significant gender and selected socioeconomic differences. More support for managing preventative medicines, of uncertain benefit, might be helpful in this population.
Authors: Annica Lagerin; Lena Törnkvist; Gunnar Nilsson; Kristina Johnell; Johan Fastbom Journal: Scand J Public Health Date: 2017-12-04 Impact factor: 3.021
Authors: Petra von Heideken Wågert; Janna Mc Gustavsson; Lillemor Lundin-Olsson; Kristina Kallin; Björn Nygren; Berit Lundman; Astrid Norberg; Yngve Gustafson Journal: Aging Clin Exp Res Date: 2006-04 Impact factor: 3.636
Authors: Carmen Martin-Ruiz; Carol Jagger; Andrew Kingston; Joanna Collerton; Michael Catt; Karen Davies; Mick Dunn; Catharien Hilkens; Bernard Keavney; Simon H S Pearce; Wendy P J den Elzen; Duncan Talbot; Laura Wiley; John Bond; John C Mathers; Martin P Eccles; Louise Robinson; Oliver James; Thomas B L Kirkwood; Thomas von Zglinicki Journal: Mech Ageing Dev Date: 2011-08-16 Impact factor: 5.432
Authors: Joanna Collerton; Karen Barrass; John Bond; Martin Eccles; Carol Jagger; Oliver James; Carmen Martin-Ruiz; Louise Robinson; Thomas von Zglinicki; Tom Kirkwood Journal: BMC Geriatr Date: 2007-06-26 Impact factor: 3.921
Authors: Christopher S Tsoi; Justin Y Chow; Kenny S Choi; Hiu-Wah Li; Jason X Nie; C Shawn Tracy; Li Wang; Ross E G Upshur Journal: BMC Res Notes Date: 2014-06-05
Authors: Andrew Kingston; Karen Davies; Joanna Collerton; Louise Robinson; Rachel Duncan; John Bond; Thomas B L Kirkwood; Carol Jagger Journal: PLoS One Date: 2014-02-07 Impact factor: 3.240